Frontida BioPharm, Inc.

Frontida BioPharm, Inc. Launches CAT.one Testing to Support Abuse-Deterrent Product Development

LogoFrontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the launch of its new Category 1 (CAT.ONETM) in vitro testing and evaluation services to support development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.

Frontida BioPharm, Inc. has Been Recognized as a Minority Owned Contract Development and Manufacturing Organization

LogoFrontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, has been granted full certifiable recognition by The Eastern Minority Supplier Development Council as a Minority-Owned Business Enterprise (certified MBE).

Frontida BioPharm, Inc. Announces Puneet Sapra as New Chief Financial Officer

LogoFrontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the appointment of Puneet Sapra as new Chief Financial Officer. Mr. Sapra will be replacing Andrew Wang, who recently accepted the CFO role at Frontage Holdings Corporation, a Contract Research Organization based in the USA and China (HK 1521).

Frontida BioPharm, Inc. Announces Praful Agrawala, Ph.D., as Executive Vice President, Technology

LogoFrontida BioPharm, Inc., a pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the appointment of Praful Agrawala, Ph.D., as Executive Vice President, Technology. Dr. Agrawala adds years of pharmaceutical product development leadership experience to Frontida after serving in executive roles at Amneal Pharmaceuticals, Sanofi-Aventis, and Schering-Plough Research Institute.

Frontida BioPharm, Inc., a Minority-Owned CDMO Announced Today the Appointment of Steven Roese as Vice President of Quality

LogoFrontida BioPharm, Inc., a minority-owned pharmaceutical Contract Development and Manufacturing Organization based in Philadelphia and Chicago areas, announced today the appointment of Steven Roese as Vice President of Quality. Mr. Roese joins Frontida with over 25 years of experience in quality operations and pharmaceutical industry management.

Frontida BioPharm, Inc. Announces Highly Potent Compound Contract Manufacturing Suite to Support Existing Product Development and Manufacturing Capabilities

LogoPhiladelphia, Pennsylvania, U.S.A. August 18, 2020 Frontida BioPharm, Inc. today announced the completion of a facility expansion to their oral solid dose manufacturing operations with the commissioning of a Highly Potent Compound Contract Manufacturing Suite. This addition features 1000 sq. ft of readily available, hazard-certified production space.

FB-HRS, LLC Announces US FDA Clearance of IND Application to Initiate Clinical Trial for FBHRS001, a Treatment for Atrial Fibrillation

LogoFB-HRS, LLC today announced the US Food and Drug Administration has cleared an Investigational New Drug (IND) application to initiate its Clinical Trial of FBHRS001, a fixed dose combination (FDC) of two drugs, for the treatment of atrial fibrillation. This FDC product is being evaluated for the improved safety and efficacy, in comparison to existing drugs on the market.